Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

about

Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab.

P2860

Q36785131-6D2598EA-7D35-40E4-8FCD-7D22217F47CD Q49499240-65136E7A-6666-4479-8794-7B38B97DCBAF

P2860

Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

Item

http://www.wikidata.org/entity/Q48468668

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

@en

Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

@nl

type

Item

label

Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

@en

Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

@nl

prefLabel

Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

@en

Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

@nl

P1476

Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

@en

P2093

John R Hesselink

http://www.w3.org/2001/XMLSchema#string

Kevin T Murphy

http://www.w3.org/2001/XMLSchema#string

Matthew J Barkovich

http://www.w3.org/2001/XMLSchema#string

Nikdokht Farid

http://www.w3.org/2001/XMLSchema#string

Santosh Kesari

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Probing tissue microstructure with restriction spectrum imaging: Histological and theoretical validation.

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Pseudoprogression and pseudoresponse in the treatment of gliomas.

Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma.

Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology.

Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.

Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.

P304

329-335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/CNS.14.35

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Karra Muller

Tyler M Seibert

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25363005

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

6113949

http://www.w3.org/2001/XMLSchema#string

Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

about

P2860

P2860

Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932